Jamieson is pleased to announce that it has advised the management team of Norgine Europe B.V. (“Norgine”) on the sale of the business to Goldman Sachs Asset Management.
Norgine is a leading European specialty pharmaceutical company with a diversified, differentiated portfolio of approximately 40 products. Norgine’s offering comprises the iconic MOVICOL brand with 25+ years’ heritage, a growing portfolio of promoted prescription products across both launch and growth stages, and a high-quality and differentiated pipeline, offering growth opportunities across multiple therapeutic areas. The Company has a proven track record developing, acquiring, and in-licensing assets, levering its fully integrated operations, which include a pan-European infrastructure and strong regulatory, market access, and launch capabilities.
Stuart Coventry, Stephen Maxwell and Henry Balcerak advised the Norgine management team on the transaction.
